Volume 6, Issue 3

Kannissery Pramod, M. Abu Tahir, Naseem A. Charoo, Shahid H. Ansari, Javed Ali

pp. 129–138 · DOI: 10.4103/2230-973X.187350

The application of quality by design (QbD) in pharmaceutical product development is now a thrust area for the regulatory authorities and the pharmaceutical industry. International Conference on Harmonization and United S…

Kenneth C. Ofokansi, Franklin C. Kenechukwu, Richard O. Ezugwu, Anthony A. Attama

pp. 139–147 · DOI: 10.4103/2230-973X.187344

Background: The purpose of this study was to develop ibuprofen (IB)-polyethylene glycol (PEG) 8000 solid dispersions (SDs) and investigate them for in vitro dissolution and in vivo anti-inflammatory activity. Materials a…

Nallaguntla Lavanya, Yallamalli Indira Muzib, Jithan Aukunuru, Umamahesh Balekari

pp. 148–157 · DOI: 10.4103/2230-973X.187351

Objective: The objective of the present work was to prepare and evaluate a novel oral formulation for systemic delivery of low molecular weight heparin (LMWH). The formulation consisted of Eudragit S 100-coated positivel…

Vaishali Thakkar, Vaishali Korat, Lalji Baldaniya, Mukesh Gohel, Tejal Gandhi, Nirav Patel

pp. 158–168 · DOI: 10.4103/2230-973X.187343

Introduction:The aim of burn management and therapy is fast healing and epithelisation to prevent infection. The present study is concerned with the development and characterization of a novel nanaoparticulate system; cu…

Govada Kishore Babu, Puttagunta Srinivasa Babu, Mukkanti Khagga

pp. 169–179 · DOI: 10.4103/2230-973X.187345

Introduction: Valsartan is a type II Biopharmaceutics Classification System (BCS) classified drug. The poor aqueous solubility restricts its use in developing sustained or controlled release systems for the treatment of …